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Idiopathic pulmonary fibrosis (IPF) is a progressive disease thought to result from 
impaired	lung	repair	following	injury	and	is	strongly	associated	with	aging.	While	vas-
cular	alterations	have	been	associated	with	IPF	previously,	the	contribution	of	lung	
vasculature during injury resolution and fibrosis is not well understood. To compare 
the role of endothelial cells (ECs) in resolving and non-resolving models of lung fi-
brosis,	we	applied	bleomycin	intratracheally	to	young	and	aged	mice.	We	found	that	
injury	in	aged	mice	elicited	capillary	rarefaction,	while	injury	in	young	mice	resulted	in	







cyclase in human lung fibroblasts reduced TGFβ-induced pro-fibrotic gene and pro-
tein	expression.	Additionally,	loss	of	eNOS	in	human	lung	ECs	reduced	the	suppres-
sion of TGFβ-induced	lung	fibroblast	activation	in	2D	and	3D	co-cultures.	Altogether,	
our results demonstrate that persistent lung fibrosis in aged mice is accompanied by 
capillary	 rarefaction,	 loss	of	EC	 identity,	and	 impaired	eNOS	expression.	Targeting	
vascular function may thus be critical to promote lung repair and fibrosis resolution 
in aging and IPF.
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1  | INTRODUC TION
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic 
interstitial	pneumonia,	and	its	incidence	and	prevalence	greatly	in-
crease	with	age	 (Lederer	&	Martinez,	2018).	 IPF	prognosis	 is	poor	
with a median survival of 2-3 years after diagnosis and a mortal-
ity	 rate	higher	 than	most	 common	cancers	 (Mora,	Rojas,	Pardo,	&	
Selman,	 2017).	 Abnormal	 wound	 healing,	 excessive	 scarring,	 and	
loss	of	gas	exchange	function	are	cardinal	features	of	IPF,	and	cur-
rent therapeutic options are limited and not able to fully reverse es-
tablished	disease	 (Somogyi	 et	 al.,	 2019).	 It	 has	been	hypothesized	
that the limited regenerative capacity of the aged lung may greatly 
influence	 lung	 repair	 and	 ultimately	 fibrosis	 resolution	 (Meiners,	
Eickelberg,	&	Konigshoff,	2015),	but	the	role	of	the	lung	vasculature	
in fibrosis and repair of the aging lung is not well studied.
Pulmonary microvasculature is abundant in mature lung and 
plays	a	critical	role	in	mediating	gas	exchange	(Aird,	2007).	In	addi-
tion	to	carrying	blood,	endothelial	cells	actively	release	angiocrine	
factors that have been shown to regulate both alveogenesis during 
mouse lung development as well as lung regeneration in adult ani-
mals	(Ding	et	al.,	2011),	making	these	cells	 important	regulators	of	
lung	 homeostasis.	 Intriguingly,	 endothelial	 dysfunction	 increases	
with advancing aging and multiple lines of research have established 
that vascular aging is a critical step in the development of numerous 
chronic	disorders	including	chronic	lung	diseases	(Polverino,	Celli,	&	
Owen,	2018;	Seals,	Jablonski,	&	Donato,	2011).	These	findings	sug-
gest that targeting specific aging-associated endothelial alterations 
may represent a therapeutic strategy to promote lung repair and halt 
disease progression.
Aberrant	vascular	remodeling	is	a	previously	noted	feature	in	the	
pathogenesis	of	 IPF,	and	 increased	capillary	 irregularities	 including	




ease	 progression	 still	 remains	 debated.	 Thus,	 understanding	 the	
roles lung vascular remodeling plays in lung repair and fibrosis in 
young and aged animal models may provide important insights in the 
pathogenesis of IPF.
Prior work with mouse models have showed that lung micro-
vasculature	 undergoes	 extensive	 remodeling	 following	 bleomy-
cin-induced	lung	injury	(Kato	et	al.,	2018).	Inhibiting	key	angiogenic	
pathways in endothelial cells (ECs) during the early injury and inflam-
matory phase post-bleomycin delivery limits fibroblast activation 
and	reduces	collagen	deposition	(Dang	et	al.,	2017;	Wan	et	al.,	2013).	
While	these	studies	suggest	that	ECs	positively	support	fibrogenic	
responses	during	 the	 early	 phase	post-injury,	 they	do	not	 provide	
specific insights on the role of the vasculature during later phases 




cular bed may play an important role during fibrosis resolution by 
limiting fibrogenic milieus and reestablishing a functional alveolar 
niche.
We	have	 recently	demonstrated	 that	 lung	 fibroblast	activation	
following bleomycin challenge is transient in young mice but more 
persistent	 in	 aged	 ones	 (Caporarello	 et	 al.,	 2019).	 Similarly,	 other	
groups have shown that fibrosis is persistent in aged mice and res-
olution	 is	markedly	 impaired	 relative	 to	young	mice	 (Hecker	et	al.,	
2014;	Podolsky	et	al.,	2020;	Torres-Gonzalez	et	al.,	2012;	Xu	et	al.,	
2009).	Thus,	 in	 this	work,	we	have	taken	advantage	of	 the	 resolv-
ing and non-resolving nature of fibrosis in young and aged mice to 
compare vascular remodeling and lung endothelial cell behavior 
associated	with	these	divergent	outcomes.	We	have	found	that	in-
jured lungs from young and aged mice displayed divergent vascular 
remodeling,	 with	 dramatic	 capillary	 rarefaction	 observed	 in	 aged	
mice	following	bleomycin	injury.	Gene	expression	analysis	of	freshly	
isolated lung ECs identified profound transcriptional changes in 
these	cells	after	injury	in	young	and	aged	mice,	including	a	marked	
reduction	of	endothelial	cell	markers	and	an	increased	expression	of	
pro-fibrotic and inflammatory markers in the ECs from aged mice. In 
addition,	we	 identified	endothelial	nitric	oxide	synthase	 (eNOS)	as	
an important player during the resolution phase of lung fibrosis that 
fails	to	increase	in	aged	mice.	Co-culture	experiments	demonstrated	
that	 lung	ECs	 restrained	 fibroblast	 activation	and	 loss	of	 eNOS	 in	
vascular cells failed to promote fibroblast deactivation.
Hence,	our	data	shed	new	light	on	the	pulmonary	vasculature	as	
an important regulator of lung fibrosis resolution and identified al-
tered transcriptional responses in lung endothelial cells during aging 
that may be targeted to promote fibrosis resolution.
2  | RESULTS
2.1 | Vascular rarefaction accompanies persistent 
fibrosis in aged mice
Numerous	studies	have	shown	that	bleomycin-induced	lung	fibrosis	
in	young	mice	resolves	over	time	(Tashiro	et	al.,	2017).	Using	Col1α1-
GFP transgenic mice in combination with fluorescence-activated cell 
sorting	 (FACS)	 analysis,	we	have	previously	 shown	a	 transient	but	






olution	 in	 young	mice	 (30	 and	 75	 days	 post-bleomycin)	 and	 com-
pared	 responses	 in	 young	 (2	months)	 and	 aged	mice	 (18	months).	
Analysis	of	body	weight	and	survival	curves	showed	no	significant	
differences for these parameters between the two groups (Figure 
S1).	As	shown	in	Figure	1b,	lung	fibroblasts	isolated	from	both	young	
and aged mice showed comparable elevation of Col1a1 transcripts 
at	 day	 30	 following	 bleomycin	 treatment.	 However,	 while	 Col1a1 
expression	trended	downwards	in	lung	fibroblasts	from	young	mice	
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at	75	days	post-bleomycin,	its	expression	remained	elevated	in	lung	
fibroblasts from aged animals at the same timepoint. These results 




mice,	 lung	fibrosis	continues	to	 increase	out	 to	day	75	following	a	
single	dose	of	bleomycin	(Figure	1d).	Histological	analysis	confirmed	
increased collagen deposition in the lungs of aged mice compared to 
those	 from	young	animals	at	75	days	post-bleomycin	 (Figure	1e,f).	
These data confirm that lungs from young animals spontaneously re-
solve from bleomycin-induced fibrosis while lungs from aged animals 
maintained elevated collagen levels.
Because	 aging-induced	 functional	 and	 structural	 alterations	
of the microcirculation contribute to the pathogenesis of a range 
of	 age-related	 diseases	 (Scioli,	 Bielli,	 Arcuri,	 Ferlosio,	 &	Orlandi,	
2014),	 we	 sought	 to	 investigate	 changes	 to	 the	 pulmonary	 vas-
culature in aged mice following lung injury. To evaluate vascular 
changes	that	are	associated	with	sustained	fibrosis,	we	immunos-
tained bleomycin-treated lung tissues from young and aged mice 
with	 an	 antibody	 against	 the	 endothelial	 cell	 marker	 PECAM-1	
followed	 by	 an	 automated	 vascular	 density	 analysis.	 While	 we	
did not observe significant differences in the vascular density 
between	young	and	aged	animals	 in	 the	absence	of	 injury,	 lungs	
from	aged	mice	exhibited	 significant	 reduction	of	 vessel	density	
at	30	and	75	days	post-bleomycin	relative	to	 injured	young	mice	
(Figure	2a,b).	These	observations	resemble	the	vascular	regression	
we observed within the fibroblastic foci (FF) of human lung tissue 
from IPF patients (Figure 2c) and are in agreement with previous 
analyses of IPF fibroblastic foci described in literature (Cosgrove 
F I G U R E  1  Delayed	fibrosis	resolution	in	aged	mice	following	bleomycin	challenge.	(a)	Young	and	aged	mice	were	exposed	to	bleomycin	
and	sacrificed	after	30	and	75	days.	Lungs	were	harvested	and	prepared	for	FACS	sorting.	(b)	Col1a1	transcriptional	analysis	of	FACS-sorted	
GFP+/CD31−/CD45−/EpCAM−	lung	fibroblasts	isolated	from	young	and	aged	animals	after	bleomycin-induced	injury	(young	sham,	N =	5;	
young	30	days,	N =	8;	young	75	days,	N =	5;	aged	sham,	N =	7;	aged	30	days,	N =	9;	aged	75	days,	N =	5).	(c)	Hydroxyproline	assay	was	
used	to	evaluate	collagen	deposition	in	the	lungs	(young	sham,	N =	8;	young	14	days,	N =	7;	young	30	days,	N =	9;	young	75	days,	N = 7). 
Data	passed	Kolmogorov–Smirnov	normality	test,	are	expressed	as	mean	± SD,	and	analyzed	using	one-way	analysis	of	variance	(followed	
by	Tukey's	post	hoc	test).	(d)	Hydroxyproline	assay	was	used	to	evaluate	collagen	deposition	in	the	lungs	(aged	sham,	N =	8;	aged	14	days,	
N =	5;	aged	30	days,	N =	11;	aged	75	days,	N =	8).	Data	passed	Kolmogorov–Smirnov	normality	test,	are	expressed	as	mean	± SD,	and	
analyzed	using	one-way	analysis	of	variance	(followed	by	Tukey's	post	hoc	test).	(e,	f).	Representative	immunohistochemistry	images	and	
quantification	of	Collagen	I	by	automated	image	analysis	(young	75	days,	N =	4;	aged	75	days,	N =	4).	Data	are	non-normally	distributed,	are	
expressed	as	median	and	IQR,	and	analyzed	using	non-parametric	Mann–Whitney	test	(*p <	0.05;	**p < 0.01).
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et	al.,	2004).	In	contrast,	lungs	of	young	mice	showed	a	significant	
but transient increase in vessel density at the same timepoints 
(Figure	2a,b).	These	data	demonstrated	that	persistent	lung	fibro-
sis	in	aged	mice	is	accompanied	by	a	reduced	vascular	density,	sug-
gesting that aging may alter lung endothelial cell responses that 
contribute to the divergent lung remodeling observed in young 
and aged mice.
2.2 | Aged mice lungs showed impaired angiogenic 
capacity ex vivo
Angiogenesis,	 the	 growth	 of	 new	 blood	 vessels	 from	 pre-existing	
ones,	plays	a	critical	role	in	tissue	injury	responses,	and	abnormal/
limited angiogenesis has been shown to contribute to the patho-
genesis	of	numerous	chronic	disorders	(Carmeliet,	2003).	Thus,	we	
reasoned that the reduced vascular density we observed in aged 
mice may be the consequence of an altered angiogenic response in 
lung ECs from these mice. In order to evaluate the angiogenic capac-
ity	of	lung	ECs	from	young	and	aged	mice,	we	generated	lung	explant	
cultures by embedding freshly cut lung tissues in collagen matrices. 
In	 this	model,	 angiogenesis	 is	 triggered	 both	 as	 a	 consequence	of	
the	injury	associated	with	the	dissection	procedure	(Ligresti,	Aplin,	
Zorzi,	Morishita,	&	Nicosia,	2011)	as	well	as	in	response	to	the	pres-
ence	 of	 exogenous	 vascular	 endothelial	 growth	 factor	 A	 (VEGFA)	
(Dang	et	al.,	2017).	The	growth	of	vessel	sprouts	from	the	lung	ex-
plants was monitored for 7 days and then quantified by counting the 
number	of	 sprouts	 in	each	 lung	explant	under	 the	microscope.	As	
shown	in	Figure	2e,f,	while	lung	explants	from	young	mice	showed	
numerous	 vessel	 sprouts,	 those	 harvested	 from	 aged	 animals	 ex-
hibited a reduced number of vessel sprouts. These results demon-
strate that lungs from aged mice have a limited angiogenic capacity 
F I G U R E  2  Vascular	rarefaction	
accompanies persistent fibrosis in aged 




75	days,	N =	9;	aged	sham,	N = 4; aged 
30	days,	N =	6;	aged	75	days,	N = 11). 
Data	passed	Shapiro–Wilk	normality	test,	
are	expressed	as	mean	± SD,	and	analyzed	
using one-way analysis of variance 
(followed by Tukey's post hoc test). (b) 
Representative IF images of mouse lung 
tissue	stained	with	PECAM-1	antibody.	
Scale	bars:	100	μm. (c) Immunostaining 




10X,	scale	bars:	100	μm. FF = fibroblastic 
foci.	Arrows	show	areas	occupied	by	
microvessels in regions bordering FF. (d) 
Schematic	for	ex	vivo	lung	tissue	culture.	
Pieces of lungs from young and aged mice 




demonstrate reduction of sprouting 
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compared	to	young	animals,	and	suggest	that	aged	ECs	may	differ	in	
their capacity to respond to injury and angiogenic stimuli.
2.3 | Loss of endothelial cell identity in the lungs of 
aged mice following bleomycin challenge
The limited angiogenic capacity of aged lung and the reduced vascu-
lar density observed in the injured lungs of these animals prompted 















array were further confirmed by qPCR on a larger number of samples 
as shown in Figure 3c.
All	 together,	 these	 data	 demonstrated	 a	 striking	 divergence	 in	
the	endothelial	gene	expression	program	that	emerges	following	in-
jury	in	young	and	aged	mice,	with	lung	ECs	from	aged	mice	acquiring	
an altered transcriptional state reminiscent of that observed during 
the	endothelial/mesenchymal	transition	(EndMT)	(Piera-Velazquez	&	
Jimenez,	2019).	These	observations	suggest	that	endothelial	 injury	
responses during aging may be a critical driver of progressive lung 
fibrosis and that reestablishing normal endothelial homeostatic and 
repair programs may provide a therapeutic strategy to promote fi-
brosis resolution.
F I G U R E  3  Loss	of	endothelial	
cell identity in the lungs of aged mice 






and aged mice (30 days) were analyzed by 
using an endothelial cell biology profiler 
PCR	Array	(N = 4 mice). The heatmap 
was generated by averaging n = 4 mice 
for	each	condition.	Sham	animals	were	
harvested at the same time of bleomycin-
treated animals. The data represent fold 
changes relative to the young sham and 
normalized to the housekeeping gene 
Actb.	(c)	Transcriptional	analysis	of	FACS-
sorted CD31+/GFP−/CD45−/EpCAM−	
lung ECs isolated from young and aged 
mice after bleomycin challenge (young 
sham,	N =	5,	young	30	days,	N = 10; aged 




using one-way analysis of variance 
(followed by Tukey's post hoc test) 
(*p <	0.05;	**p <	0.01;	***p < 0.001).
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2.4 | Loss of eNOS leads to sustained lung fibrosis 
in young animals following bleomycin challenge
Our	endothelial	gene	expression	analysis	of	injured	young	and	aged	
lungs revealed that several genes involved in vascular remodeling 
and angiogenesis were significantly reduced in lung ECs from aged 
mice.	Among	these	was	nitric	oxide	synthase	3	(Nos3,	encoding	en-
dothelial	NOS,	eNOS),	eNOS	is	predominantly	expressed	in	ECs	and	
belongs to a family of enzymes catalyzing the production of nitric 
oxide	(NO),	a	gaseous	molecule	that	binds	and	activates	the	receptor	
F I G U R E  4  Loss	of	eNOS	leads	to	sustained	lung	fibrosis	in	young	animals	following	bleomycin	challenge.	(a)	Nos3 transcriptional 
analysis	of	FACS-sorted	CD31+/GFP−/CD45−/EpCAM−	lung	ECs	isolated	from	young	and	aged	mice	after	bleomycin-induced	lung	injury	




N =	10;	eNOS−/−	sham,	N =	7;	eNOS−/−	11	days,	N =	3;	eNOS−/−	60	days,	N =	14).	Data	passed	Shapiro–Wilk	normality	test,	are	expressed	
as mean ± SD,	and	analyzed	using	one-way	analysis	of	variance	(followed	by	Tukey's	post	hoc	test).	(d)	Masson's	trichrome	assay	was	used	
to	stain	lung	tissue.	(e)	Transcriptional	analysis	of	whole	lung	homogenates	obtained	from	WT	and	eNOS−/−	mice	(WT	60	days,	N = 7; 
eNOS−/−	60	days,	N =	4).	The	reference	group	throughout	all	the	genes	analyzed	in	this	panel	is	WT	60	days	after	bleomycin.	Data	passed	
Kolmogorov–Smirnov	normality	test,	are	expressed	as	mean	± SD,	and	analyzed	using	Student's	t	test	(*p <	0.05;	**p < 0.01).
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2011;	 Knorr	 et	 al.,	 2008;	 Stasch,	 Schlossmann,	 &	 Hocher,	 2015;	
Wang	et	al.,	2006).	Thus,	we	hypothesized	that	absence	of	enhanced	
eNOS	expression	in	lung	ECs	from	aged	mice	may	contribute	to	the	
sustained fibroblast activation and reduced fibrosis resolution we 




we observed that Nos3	gene	expression	was	significantly	elevated	
at	 30	 days	 and	 returned	 to	 baseline	 at	 75	 days	 post-bleomycin	
(Figure	4a).	In	contrast,	ECs	from	aged	mice	showed	no	increase	in	











60	 in	WT	mice	 but	 remaining	 significantly	 elevated	 in	 lungs	 from	
eNOS−/−	 mice	 at	 the	 same	 timepoint.	 Lung	 histological	 examina-
tion confirmed increased collagen in the lungs of bleomycin-treated 




including the mitochondrial regulator Ppargc1a whose repression is 
critical during the transition of fibroblasts from a quiescent to an ac-
tivated	state	(Caporarello	et	al.,	2019).	qPCR	analysis	of	whole	lung	
post-bleomycin	revealed	increased	pro-fibrotic	gene	expression,	in-
cluding Col1a1, Fn1, and Acta2,	 and	a	 reduction	of	 the	anti-fibrotic	
gene Ppargc1a	in	eNOS−/−	mice	compared	to	WT	animals	(Figure	4e).	
Interestingly,	injured	lungs	from	eNOS−/− mice also showed reduced 
expression	of	 the	endothelial	 cell	markers	Flk1, Vwf, Cdh5, and Erg 
relative	to	lungs	from	WT	animals	(Figure	4e),	recapitulating	the	al-
tered transcriptional responses observed in lung ECs from aged mice 
post-bleomycin	 treatment.	All	 together,	 these	 results	demonstrate	
that	vascular	eNOS	plays	a	critical	role	during	the	resolution	of	bleo-
mycin-induced lung fibrosis.
2.5 | eNOS promotes lung fibroblast deactivation 




pathological conditions and small molecule activators/stimulators 
of this pathway are currently being used in the clinic to treat pa-
tients	with	pulmonary	hypertension	(Ghofrani	&	Grimminger,	2009).	
To investigate the contribution of sGC activation in inhibiting pro-
fibrotic	gene	expression,	we	treated	human	lung	fibroblasts	(HLFs)	
with TGFβ	for	48	hr	in	the	presence	or	absence	of	the	sGC	stimula-
tor	BAY	41-2272	or	 the	 sGC	activator	BAY	60-2770.	As	 shown	 in	
Figure	 5a,b,	 both	 compounds	 significantly	 reduced	 TGFβ-induced 
ACTA2,	 COL1A1,	 and	 FN1	 expression	 at	 RNA	 and	 protein	 levels.	
Figure	5a,b	compares	to	HLFs	treated	with	TGFβ alone.
To test the ability of ECs to deactivate fibroblasts through the 
eNOS	pathway,	we	co-cultured	TGFβ-primed	HLFs	with	human	lung	
microvascular	endothelial	cells	(HLMECs)	that	have	been	previously	
treated	 with	 a	 siRNA	 targeting	 eNOS.	 As	 shown	 in	 Figure	 5d,e,	
TGFβ–primed	 HLFs	 co-cultured	 for	 3	 days	 with	 eNOS-silenced	
HLMECs	showed	a	 trend	upwards	 in	αSMA	 intensity	compared	 to	
HLFs	that	were	co-cultured	with	HLMECs	transfected	with	a	control	
siRNA.	 Analysis	 of	 inflammatory/fibrotic	 (IL6 and IL11) and endo-




ited by the distance between cells. To overcome this limitation and 
to	further	confirm	the	capacity	of	NO	to	influence	pro-fibrotic	gene	
expression	 in	 lung	 fibroblasts,	we	adapted	a	3D	culture	 system	 in	
which	cells	are	mixed	within	the	same	matrix	 (Tan,	Choi,	Sicard,	&	
Tschumperlin,	 2017).	 FACS-sorted	 Col1α1-GFP mouse lung fibro-
blasts were primed with TGFβ for 24 hr and subsequently co-cul-
tured	 with	 eNOS-silenced	 HLMECs	 or	 control	 silenced	 cells	 in	 a	
3D matrigel gel for additional 72 hr. To identify fibroblast-specific 
transcriptional	 changes	 in	 our	 3D	 co-culture	 system,	we	designed	
primers that recognized mouse-specific sequences in transcripts for 
analysis	by	qPCR	(Table	1).	As	shown	in	Figure	5j,	mouse	lung	fibro-
blasts	 cultured	with	 eNOS-silenced	HLMECs	 showed	 a	 significant	
increase in Acta2 and Col1a1	 gene	 expression	 compared	 to	 those	
cultured	with	control	HLMECs.	All	together,	these	findings	demon-
strated that ECs have the capacity to alter fibroblast activation and 
promote	their	deactivation	in	an	eNOS-dependent	manner,	suggest-
ing that the absence of induced NOS3	expression	in	the	lungs	of	aged	
mice following injury may directly contribute to the perpetuation of 
fibroblast activation and fibrosis progression observed in the aging 
lung.
3  | DISCUSSION
IPF	 is	 characterized	 by	 the	 excessive	 accumulation	 of	 extracellu-
lar	matrix	 that	 leads	 to	 distortion	 of	 lung	 architecture	 and	 loss	 of	
organ	function.	Myofibroblasts	are	the	main	source	of	ECM	in	 IPF	
lungs and their sustained pathological activation is primarily re-
sponsible	 for	 the	 progressive	worsening	 of	 the	 disease	 (Moore	 &	
Herzog,	 2013).	 Dysregulated	 epithelium/mesenchyme	 cross	 talk,	
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unresolved	inflammation,	and	limited	lung	regenerative	capacity	are	
among the causes thought to lead to the sustained myofibroblast 
activation	 and	 consequently	 unresolved	 fibrosis	 (Wolters,	 Collard,	
&	Jones,	2014).	In	this	regard,	little	is	known	about	the	possible	link	
between	aberrant	fibrosis	resolution	and	vascular	remodeling,	and	
elucidation of this interaction is essential to better understand lung 









(72 hr). N =	4	independent	experiments.	Data	passed	Kolmogorov–Smirnov	normality	test,	are	expressed	as	mean	±	SD,	and	analyzed	using	
Student's	t	test.	(h,	i)	Schematic	of	3D	co-cultures	generation.	Visualization	of	DiI-labeled	HLMECs	(red)	and	Col1α1-GFP mouse fibroblasts 
(green)	within	an	endothelial	cell	fibroblast	3D	co-culture.	Scale	bar:	500	μm.	(j)	Gene	expression	analysis	of	fibroblasts	transcripts	from	
mouse fibroblasts alone versus co-cultures with control- and NOS3	siRNA	transfected	HLMECs	at	day	3.	N =	3	independent	experiments.	
Data	passed	Shapiro–Wilk	normality	test,	are	expressed	as	mean	± SD,	and	analyzed	using	one-way	analysis	of	variance	(followed	by	Tukey's	
post	hoc	test).	(**p <	0.01;	***p < 0.001).





tions during aging contribute to persistent lung fibrosis may lead to 
novel therapeutic approaches.
In order to identify altered molecular pathways in the pulmonary 
vasculature	that	may	contribute	to	sustained	fibrosis,	we	evaluated	
the responses of lung ECs and fibroblasts to bleomycin-induced 
lung	injury	and	fibrosis	in	young	and	aged	mice.	By	combining	FACS	
sorting,	gene	expression,	and	imaging	analysis	on	injured	lungs	from	
both	 young	 and	 aged	mice,	we	 demonstrated	 that	 lung	 fibroblast	
activation in young mice post-bleomycin is transient and is accom-
panied	by	a	significant	 increase	 in	vessel	density.	On	the	contrary,	
fibroblasts	isolated	from	aged	lungs	post-bleomycin	exhibited	a	per-




been reported in multiple other mouse models of fibrosis in young 
mice,	 including	scleroderma	and	kidney	fibrosis	 (Loganathan	et	al.,	
2018;	Trojanowska,	2010).	Additionally,	it	has	been	shown	that	the	
loss of capillaries observed in these fibrosis models leads to sec-
ondary	events	 including	 tissue	hypoxia	and	oxidative	 stress	which	
further	 exacerbate	 fibrosis	 progression	by	promoting	proliferation	
and	 activation	 of	 tissue	 resident	 fibroblasts	 (Basile	 et	 al.,	 2011;	
Fleming	et	al.,	2008).	Our	findings	are	in	part	consistent	with	these	
previous	observations,	but	only	 in	aged	mice.	 In	contrast,	bleomy-
cin-treated lungs from young animals showed a significant increase 
in	vessel	density	at	30	days,	suggesting	a	potential	active	role	for	the	
lung	vascular	bed	during	 fibrosis	 resolution.	 Intriguingly,	 the	capil-
lary rarefaction we observed in the injured lungs from aged mice 
is consistent with the non-resolving nature of this animal model of 
fibrosis,	strongly	suggesting	that	aging	may	lead	to	a	progressive	de-
cline of lung endothelial cell functions thereby influencing fibrosis 
resolution following lung injury.
Moreover,	our	ex	vivo	results	from	mouse	lung	explants	are	con-
sistent with the in vivo observations and demonstrated that while 
lung	explants	from	young	mice	responded	to	angiogenic	stimuli	and	
generated	 numerous	 vessel	 sprouts,	 lung	 explants	 isolated	 from	
aged mice are refractory to angiogenesis and showed a limited num-
ber of microvessels upon angiogenic stimulation. These observations 





due to an impaired endothelial cell migration through a stiff micro-
environment may be responsible for the altered vascular remodeling 
in injured aged lungs.
In	addition,	we	found	that	lung	ECs	isolated	from	aged	lungs	after	
injury have a significant reduction in endothelial markers and an en-
richment	 in	 inflammatory	and	fibrotic	markers,	which	 is	consistent	
with	 the	 transcriptional	 switch	observed	during	EndMT,	a	process	
observed	 in	 several	 chronic	 conditions	 including	 atherosclerosis,	
pulmonary	hypertension,	and	organ	fibrosis	(Gong,	Lyu,	Wang,	Hu,	
&	Zhang,	2017;	Kitao	et	al.,	2009).	During	this	process,	endotheli-
al-specific markers are lost while mesenchymal and inflammatory 
markers	are	acquired,	together	with	alterations	in	cellular	morphol-
ogy	and	 functions,	 including	 loss	of	 the	ability	of	endothelial	 cells	
to	 organize	 in	 vessel-like	 structures	 (Piera-Velazquez	 &	 Jimenez,	
2019).	Moreover,	 TGFβ,	which	 is	 highly	 abundant	 in	 fibrotic	 lungs	
(Yue,	Shan,	&	Lasky,	2010),	plays	an	 important	 role	during	EndMT	


















TA B L E  1  Mouse	and	human	primer	
sequences for qPCR analysis
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that	VEGF,	whose	levels	are	reduced	in	IPF	patients	(Barratt,	Flower,	




microenvironment which can influence both endothelial cell fate 
and	 consequently	 fibroblast	 activation.	 Interestingly,	 in	 line	 with	
our	results,	altered	endothelial	cell	activation	and	abnormal	vascu-
lar	 remodeling	 also	occurs	 in	 an	experimental	model	 of	 persistent	
lung fibrosis which is triggered by repetitive doses of bleomycin (Cao 
et	al.,	2016).	Hence,	our	findings	suggested	that	aging	leads	to	the	
formation of an unfavorable lung microenvironment that promotes 




preservation,	 endothelial	 cell	 survival,	 and	 apoptosis	 (Dimmeler	&	









olution post-injury and failure to activate this pathway in the lungs 
of	aged	mice	contributes	to	sustained	fibrogenesis.	Interestingly,	in	
line	with	our	 results	 in	 the	absence	of	 injury,	a	 recent	study	using	
single-cell	 RNA	 sequencing	 reported	no	differences	 in	 lung	 endo-
thelial Nos3	expression	in	aged	vs	young	mice	(Angelidis	et	al.,	2019).	
However,	 single-cell	RNA	sequencing	data	 for	NOS3	expression	 in	
endothelial cells of IPF versus normal lungs were more variable. In 
agreement	with	our	results,	NOS3	expression	in	arterial	endothelial	
cells	 of	 IPF	 lung	was	 reduced;	 however,	 an	 elevation	or	 no	differ-
ences	in	other	vascular	cell	types	were	found	(Adams	et	al.,	2019),	
suggesting that regulation of NOS3 during disease may occur differ-
ently	across	 the	endothelial	 cell	 types.	Together,	our	observations	
shed	 light	 on	 the	 active	 role	 of	 eNOS	pathway	 in	 promoting	 lung	
fibrosis resolution in young mice that is lost with aging. These obser-
vations are in line with other studies reporting a protective role for 
eNOS	in	experimental	models	of	cardiac	and	renal	fibrosis	(Kazakov	
et	al.,	2013;	Nakayama	et	al.,	2009).
The increased capillary loss we observed in the lungs of aged 
mice and the lack of transcriptional activation of Nos3 gene in aged 
ECs	 leads	 us	 to	 hypothesize	 that	 eNOS/NO	 pathway	 may	 play	 a	
critical role in promoting endothelial cell survival following lung 
injury.	 Interestingly,	 previous	 studies	 have	 reported	 that	 NO	 can	
protect	 ECs	 from	 apoptosis	 through	multiple	mechanisms,	 includ-
ing	 blocking	 caspase	 activation	 (Kim,	Kwon,	Chung,	&	Kim,	 2002)	
and	by	promoting	survival	signaling	(Dimmeler	&	Zeiher,	1999).	Our	
observations together with previous reports suggest that the re-
duced	NO	availability	in	the	lungs	of	aged	mice	during	the	resolution	
phase of bleomycin-induced lung injury may limit endothelial cell 
survival thereby contributing to the sustained lung fibrosis in these 
animals.	 Another	 intriguing	 aspect	 related	 to	 the	 beneficial	 effect	
of	NO	 is	 its	 capability	 to	 suppress	 the	 nucleotide-binding	 domain	
and	 leucine-rich	 repeat	containing	 family,	pyrin	domain	containing	
3	 (NLRP3)	 inflammasome	 in	 lungs	 (Mishra	et	al.,	2013).	NLRP3	 in-




age-matched	 counterparts	 (Stout-Delgado	 et	 al.,	 2016).	 Thus,	 we	
speculate	 that	 NO-NLRP3	 cross	 talk	may	 be	 another	 anti-fibrotic	
mechanism in lung that is lost with aging.
While	the	role	of	NO/sGC	in	regulating	vascular	tone	by	promot-
ing	smooth	muscle	cells	(SMCs)	relaxation	has	been	investigated	in	
great	depth	 (Park	et	al.,	2019;	Tsai	&	Kass,	2009),	 its	 contribution	
to	 lung	 fibroblast	 biology	 and	 ECM	 remodeling	 has	 just	 begun	 to	
emerge	 (Dunkern,	 Feurstein,	Rossi,	 Sabatini,	&	Hatzelmann,	2007;	
Lambers	et	al.,	2019).	Our	findings	demonstrate	that	in	addition	to	
inhibiting αSMA	expression,	activation	of	sGC	signaling	pathways	in	
lung fibroblasts greatly reduces TGFβ	responses,	including	collagen	
synthesis. Given that ECs can influence the lung microenvironment 
by	 producing	 and	 releasing	 angiocrine	 factors,	 in	 this	 study,	 we	
wanted to determine whether lung ECs can directly alter fibroblast 
activation. Our in vitro results strongly support a functional role for 
ECs in facilitating the return of activated fibroblasts to a less ac-
tivated	state.	While	additional	work	 is	needed	 to	 fully	understand	
endothelial/mesenchymal	interactions	during	lung	fibrosis,	our	work	
highlights the concept that the lung vascular bed plays an active role 
during	 lung	 fibrosis	 resolution	 through	 the	 release	of	NO	and	 the	




raised several questions not addressed in this study. Investigations 
aimed at understanding whether restoring Nos3	expression	in	aged	
animals may have beneficial effects in reestablishing endothelial 
homeostasis and limiting lung fibrosis may be an interesting future 
subject	of	study.	While	our	study	highlighted	the	important	role	of	
eNOS/NO/sGC	 during	 lung	 fibrosis	 resolution,	 a	 clinical	 trial	 con-






a more suitable therapeutic intervention for treatment of IPF.
Our observations set the stage for future investigations aimed at 
identifying additional endothelial-derived signals lost with aging that 
can influence fibroblast activation as well as the integrity of other 
neighboring	cells,	for	instance	epithelial	cells.	In	fact,	recent	obser-
vations highlighted an important role for ECs in creating a niche for 
epithelial cells that protect from cell injury and promote repair (Cao 




contribution of the pulmonary vascular bed during lung repair and fi-
brosis	resolution	that	is	lost	with	aging,	suggesting	that	preserving	or	
rescuing the normal vascular repair and homeostasis responses could 
represent a new therapeutic strategy to limit lung fibrosis progression.
4  | E XPERIMENTAL PROCEDURES
Detailed	methods	are	provided	in	Appendix	S1.
4.1 | Mice
Female and male Col1α1-GFP	transgenic	mice	(FVB	strain)	were	pro-














Mice	 were	 anesthetized	 with	 ketamine/xylazine	 solution	 and	 per-
fused	 via	 left	 ventricle	with	 cold	 PBS.	 The	 lungs	were	 immediately	
harvested and the single cell suspension was obtained as detailed 
in	Appendix	S1.	The	single	cell	suspension	was	 incubated	with	anti-
















Lung	 tissue	 from	 patients	 with	 IPF	 and	 from	 non-fibrotic	 healthy	
controls	was	 obtained	 from	Dr.	 Steven	Huang	 at	 the	University	 of	
Michigan.	Diagnoses	of	patients	with	IPF	were	established	by	clinic-











RNA	 interference	 was	 performed	 with	 siGENOME	Non-Targeting	
Control	 siRNA	 Pool	 #1	 (D-001206-13-05)	 or	 siGENOME	 Human	
NOS3	 siRNA	 (M-006490-00-0005)	 by	 using	 Lipofectamine	
RNAiMAX	reagent	(Thermo	Fisher	Scientific,	Cat#	13778075)	as	de-
scribed	in	Appendix	S1.
4.8 | 2D co-culture and αSMA	staining
Co-cultivation	 of	 HLFs	 and	 HLMECs	 and	 αSMA	 staining	 were	
performed by using μ-Slide	 2	 well	 Co-culture	 (ibidi,	 Lochhamer,	
Germany).	HLFs	were	primed	with	TGFβ (2 ng/ml) for 24 hr and then 
transferred into the inner minor well of the μ-Slide.	HLMECs	were	
transfected	 with	 Non-Targeting	 or	 NOS3	 siRNA.	 Six	 hours	 after	
transfection,	 the	 cells	were	 lifted	 and	plated	 into	 the	outer	minor	
wells of the μ-Slide.	After	72	hr,	HLFs	were	processed	and	stained	as	
described	in	Appendix	S1.
4.9 | 3D co-culture generation and analysis
A	 mixture	 of	 FACS-sorted	 Col1α1-GFP mice fibroblasts and 
HLMECs	was	plated	in	a	1:1	solution	of	Matrigel	Matrix	(Corning,	
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Cat#	354248)	 and	 endothelial	 cell	 growth	 basal	medium	 (Lonza,	





Mouse	 lung	 tissue	 sections	 (7	μm)	were	permeabilized,	blocked,	
and	 stained	 with	 PECAM-1	 antibody	 (dilution	 1:100;	 BD	
Biosciences,	Cat#	550274),	and	nuclei	were	counterstained	with	
DAPI	 (dilution:	 1:1000;	 Biolegend,	 Cat#422801)	 as	 described	 in	
Appendix	S1.
4.11 | Ex vivo lung tissue culture











Individual data points are shown in all plots and represent data 
from independent mice or biological replicates from cell culture 
experiments.	 Statistical	 analysis	was	 performed	 using	 Student's	
t	 test,	 one-way	 analysis	 of	 variance	 (followed	 by	 Tukey's	 post 
hoc	 test),	 or	 non-parametric	 Mann–Whitney	 test	 as	 detailed	
in	 Appendix	 S1.	 All	 analyses	 and	 plots	 were	 generated	 using	
GraphPad	 Prism	 8.0	 (La	 Jolla,	 CA,	 USA)	 with	 statistical	 signifi-
cance defined as p <	0.05.
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